PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-142.73%
Both yoy net incomes decline, with GNPX at -17.92%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
55.79%
D&A growth of 55.79% while GNPX is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
71.34%
Deferred tax of 71.34% while GNPX is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-22.08%
Both cut yoy SBC, with GNPX at -51.17%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
83.34%
Less working capital growth vs. GNPX's 193.21%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.76%
A yoy AP increase while GNPX is negative at -231.79%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-41.25%
Negative yoy usage while GNPX is 214.13%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-22.08%
Negative yoy while GNPX is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
9.39%
Operating cash flow growth 1.25-1.5x GNPX's 7.14%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.94%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-35.14%
Both yoy lines negative, with GNPX at -71.09%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.